title: Evaluation of an intermittent six-month regimen in new pulmonary tuberculosis patients with diabetes mellitus.
abstract: BACKGROUND
  The treatment of tuberculosis (TB) with category I regimen of the Revised National Tuberculosis Control Programme (RNTCP) for patients with diabetes mellitus (DM) needs evaluation.
  
  
  OBJECTIVE
  To assess the cure and relapse rates in 3 years, among the new smear-positive TB patients with Type-2 DM (DMTB) treated with CAT-I regimen (2E3H3R3Z3/4R3H3) of RNTCP.
  
  
  METHODS
  TB suspects attending the diabetology units and the TB research centre (TRC) Chennai, were investigated. Eligible DMTB cases were enrolled. Baseline estimation of cardiac, renal, liver function tests and glycosylated-HBA1c were undertaken. All patients received 2E3H3R3Z3/4R3H3 under supervision at TRC. Clinical and sputum (smear and culture) examinations and monitoring of diabetic status were undertaken every month up to 24 months, then once in 3 months up to 36 months.
  
  
  RESULTS
  Of 100 patients admitted, 7 were excluded for various reasons from analysis. Of 93 patients, 87 (94%) had a favourable response at the end of treatment. Pre and post treatment mean glycosylated-HBA1c were 9.7% and 8.4% (>7% poor control). During follow-up period, 6 died and one lost to follow-up. Of the remaining, four relapsed.
  
  
  CONCLUSIONS
  Category-I regimen, recommended for all the new smear-positive patients in the Indian TB programme, is effective in the treatment of DMTB patients, despite poor control of diabetes.
authors: Tuberculosis Research Centre (ICMR), Chennai.
authors: Rani
authors: R
authors: Balasubramanian
authors: Usha
authors: U
authors: Ramanathan
authors: K
authors: K
authors: Thyagarajan
authors: Rajeswari
authors: R
authors: Ramachandran
authors: K
authors: K
authors: Rajaram
authors: D
authors: D
authors: Bhaskar
authors: Shantharam
authors: R S
authors: RS
authors: Hariharan
authors: P R
authors: PR
authors: Narayanan
mesh_terms: D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use; D048909:Diabetes Complications / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011859:Radiography; D012008:Recurrence; D013183:Sputum / Q000382:microbiology; D013997:Time Factors; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents